Short sellers are piling into vulnerable names. Chewy remains the most heavily shorted mid-cap in the US. Short interest sits at 72.4% of free float. Sable Offshore saw the week's biggest jump — SI surged 7.7 percentage points to 36.2%. Zero shares are available to borrow there. Lucid Group tells a different story. Bears trimmed positions after a Q2 delivery beat and leadership shake-up. Cost to borrow remains at 45.5%. Availability is just 0.1% — a textbook squeeze setup.
Pharma and biotech are generating the most cross-asset noise today. EXEL options traders are alarmed — the put-call ratio hit 1.33, more than four standard deviations above its 20-day average. Short interest is already near 15% of free float. RBC raised targets on VRTX to $570 and BIIB to $242. Both remain Buy-rated. Erste Group delivered the day's biggest surprise, downgrading from Buy to Hold at a $1.78 trillion market cap.
DAL is the marquee name this week. Delta Air Lines reports Q2 Thursday morning. Travel demand signals will set the tone for the entire sector. PEP drops its Q2 earnings call Tuesday. Pricing power is the key question. LEVI also reports Tuesday after the close.
SpaceX is drawing fresh Wall Street attention after Morgan Stanley initiated coverage with a $300 target. The Bank of England is set to ease capital rules for UK lenders. Fed Governor Christopher Waller backed incoming chair Kevin Warsh's push to rethink forward guidance. Chip stocks remain under pressure after DeepSeek reported it is developing its own AI processor, a direct headwind for NVDA.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
